In a television appearance April 10, Spitzer said investigators were looking at “pricing and the integrity of drugs, whether or not there are drugs that are being adulterated, that are being tampered with. . .” He said the potential problems were due to “porous holes” in the drug distribution process.
When asked if he believed there were “fake” or “diluted” drugs in the supply chain, Spitzer responded: “There certainly are some. The question is to what magnitude.” —Arnie Orloski
